인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
Caspofungin is an echinocandin antifungal agent active against Aspergillus, Candida.This study was performed to evaluate the appropriateness of use of caspofungin according to the criteria modified from IDSA (Infectious Disease Society of America) and Korea health insurance guidelines. The study was conducted through retrospective chart review of 67 people, 69 cases of inpatients who received caspofungin in Seoul National University Hospital from January 2008 to August 2010.The use of caspofungin was highly appropriate (93.5%). The initial and maintenance dosage of caspofungin was appropriate in 79.7% of the cases. Duration of therapy was appropriate in 76.8% of patients. Caspofungin has known interactions with HIV medications (efavirenz. nevirapine), phenytoin, dexamethasone, rifampin, carbamazepine, calcineurin inhibitors (cyclosporine,tacrolimus). Drugs coadministered with caspofungin consisted of G-CSF (31 cases), granulocyte infusion (7 cases) phenytoin (1 case), Dexamethasone (1 case), Tacrolimus (5 cases), and Cyclosporine (5 cases).Caspofungin was properly used according to the criteria in 88-100% of cases. Complications occurred in 45 cases, including increasing serum potassium levels (16 cases), hepatotoxicity (13 cases), fever (10 cases) and nausea, vomiting, and diarrhea. At the end of the caspofungin therapy, there were successful outcomes in 56.82% of the patients. The death rate at 7 days after treatment was 20.6%.
상세정보 수정요청해당 페이지 내 제목·저자·목차·페이지정보가 잘못된 경우 알려주세요!
목차
등록된 정보가 없습니다.
참고문헌
참고문헌 신청최근 본 자료
